The “Shield Sign” in Two Men with Metastatic Salivary Duct Carcinoma to the Skin: Cutaneous Metastases Presenting as Carcinoma Hemorrhagiectoides

Por Cohen, Philip R., Prieto, Victor G., Piha-Paul, Sarina A., Kurzrock, Razelle
Publicado em 2012

Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temsirolimus

Por Piha-Paul, Sarina A., Shin, Sang Joon, Vats, Tribhawan, Guha-Thakurta, Nandita, Aaron, Joann, Rytting, Michael, Kleinerman, Eugenie, Kurzrock, Razelle
Publicado no Anticancer Res (2014)

Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumors

Por Piha-Paul, S.A., Munster, P.N., Hollebecque, A., Argilés, G., Dajani, O., Cheng, J.D., Wang, R., Swift, A., Tosolini, A., Gupta., S.
Publicado no Eur J Cancer (2015)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

Por Piha-Paul, Sarina A., Wheler, Jennifer J., Fu, Siqing, Levenback, Charles, Lu, Karen, Falchook, Gerald S., Naing, Aung, Hong, David S., Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicado em 2014

Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutat...

Por Wheler, Jennifer J., Tsimberidou, Apostolia M., Falchook, Gerald S., Zinner, Ralph G., Hong, David S., Fok, Jansina Y., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Kurzrock, Razelle
Publicado em 2013

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy

Por Wheler, J. J., Falchook, G. S., Tsimberidou, A. M., Hong, D. S., Naing, A., Piha-Paul, S. A., Chen, S. S., Fu, S., Stephen, B., Fok, J. Y., Janku, F., Kurzrock, R.
Publicado em 2013

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

Por Falchook, Gerald S., Naing, Aung, Wheler, Jennifer J., Tsimberidou, Apostolia M., Zinner, Ralph, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Janku, Filip, Hess, Kenneth R., Bastida, Christel, Kurzrock, Razelle
Publicado no Oncoscience (2014)

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials

Por Janku, Filip, Wheler, Jennifer J., Naing, Aung, Falchook, Gerald S., Hong, David S., Stepanek, Vanda M., Fu, Siqing, Piha-Paul, Sarina A., Lee, J. Jack, Luthra, Rajyalakshmi, Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicado em 2012

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer

Por Falchook, Gerald S., Naing, Aung, Hong, David S., Zinner, Ralph, Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Morgan-Linnell, Sonia K., Jiang, Yunfang, Bastida, Christel, Wheler, Jennifer J., Kurzrock, Razelle
Publicado em 2013

Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit

Por Fu, Siqing, McQuinn, Lacey, Naing, Aung, Wheler, Jennifer J., Janku, Filip, Falchook, Gerald S., Piha-Paul, Sarina A., Tu, Dennis, Howard, Adrienne, Tsimberidou, Apostolia, Zinner, Ralph, Hong, David S., Kurzrock, Razelle
Publicado em 2013

A Phase 1 Study of Anti-TGFβ Receptor Type-II Monoclonal Antibody LY3022859 in Patients with Advanced Solid Tumors

Por Tolcher, Anthony W., Berlin, Jordan D., Cosaert, Jan, Kauh, John, Chan, Emily, Piha-Paul, Sarina A., Amaya, Alex, Tang, Shande, Driscoll, Kyla, Kimbung, Richard, Prasad Kambhampati, S. R., Gueorguieva, Ivelina, Hong, David S.
Publicado no Cancer Chemother Pharmacol (2017)

Signature program: a platform of basket trials

Por Slosberg, Eric D., Kang, Barinder P., Peguero, Julio, Taylor, Matthew, Bauer, Todd M., Berry, Donald A., Braiteh, Fadi, Spira, Alexander, Meric-Bernstam, Funda, Stein, Steven, Piha-Paul, Sarina A., Salvado, August
Publicado no Oncotarget (2018)

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

Por Falchook, Gerald S., Wheler, Jennifer J., Naing, Aung, Piha-Paul, Sarina A., Fu, Siqing, Tsimberidou, Apostolia M., Hong, David S., Janku, Filip, Zinner, Ralph, Jiang, Yunfang, Huang, Mei, Lin, Quan, Parkhurst, Kristin, Kurzrock, Razelle
Publicado no Invest New Drugs (2014)

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

Por Falchook, Gerald S., Moulder, Stacy, Naing, Aung, Wheler, Jennifer J., Hong, David S., Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Fu, Siqing, Zinner, Ralph, Janku, Filip, Jiang, Yunfang, Huang, Mei, Parkhurst, Kristin L., Kurzrock, Razelle
Publicado no Invest New Drugs (2014)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors

Por Jardim, Denis L., Wheler, Jennifer J., Hess, Kenneth, Tsimberidou, Apostolia M., Zinner, Ralph, Janku, Filip, Subbiah, Vivek, Naing, Aung, Piha-Paul, Sarina A., Westin, Shannon N., Roy-Chowdhuri, Sinchita, Meric-Bernstam, Funda, Hong, David S.
Publicado em 2014

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

Por Wheler, Jennifer J., Moulder, Stacy L., Naing, Aung, Janku, Filip, Piha-Paul, Sarina A., Falchook, Gerald S., Zinner, Ralph, Tsimberidou, Apostolia M., Fu, Siqing, Hong, David S., Atkins, Johnique T., Yelensky, Roman, Stephens, Philip J., Kurzrock, Razelle
Publicado em 2014

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

Por Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R., Glisson, Bonnie S., Kies, Merrill S., Tsimberidou, Apostolia M., Wheler, Jennifer J., Zinner, Ralph G., Hong, David S., Kurzrock, Razelle, Piha-Paul, Sarina A.
Publicado no Oncotarget (2016)

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

Por Janku, Filip, Tsimberidou, Apostolia M., Garrido-Laguna, Ignacio, Wang, Xuemei, Luthra, Rajyalakshmi, Hong, David S., Naing, Aung, Falchook, Gerald S., Moroney, John W., Piha-Paul, Sarina A., Wheler, Jennifer J., Moulder, Stacy L., Fu, Siqing, Kurzrock, Razelle
Publicado em 2011

Phase I Study of Anti-VEGF Monoclonal Antibody Bevacizumab and Histone Deacetylase Inhibitor Valproic Acid in Patients with Advanced Cancers

Por Wheler, Jennifer J., Janku, Filip, Falchook, Gerald S., Jackson, Tiffiny L., Fu, Siqing, Naing, Aung, Tsimberidou, Apostalia M., Moulder, Stacy L., Hong, David S., Yang, Hui, Piha-Paul, Sarina A., Atkins, Johnique T., Garcia-Manero, Guillermo, Kurzrock, Razelle
Publicado em 2014

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

Por Janku, Filip, Wheler, Jennifer J., Naing, Aung, Stepanek, Vanda M., Falchook, Gerald S., Fu, Siqing, Garrido-Laguna, Ignacio, Tsimberidou, Apostolia M., Piha-Paul, Sarina A., Moulder, Stacy L., Lee, J. Jack, Luthra, Rajyalakshmi, Hong, David S., Kurzrock, Razelle
Publicado em 2012